Three-year OS was significantly reduced in patients aged ≥ 55 years compared to younger patients (21% vs 60%, p < 0.0001), in case of secondary AML (20% vs 43% in de novo leukemia, p = 0.0004), and in CD34 positive cases (23%, vs 53% in CD34- patients, p < 0.0001). This evidence concerns the gene CD34 and acute myeloid leukemia.